

1 *Exosome Secretion by Leishmania infantum modulate innate and adaptive immune responses*  
2 *and create an environment permissive for early infection.*

3

4 **Germano Castelli<sup>1</sup>, Federica Bruno<sup>1</sup>, Laura Saieva<sup>2</sup>, Riccardo Alessandro<sup>2</sup>, Luca Galluzzi<sup>3</sup>,**  
5 **Aurora Diotallevi<sup>3</sup>, Fabrizio Vitale<sup>1\*</sup>.**

6

7 **Author affiliations: <sup>1</sup>National Reference Center for Leishmaniasis (C.Re.Na.L.), Istituto**  
8 **Zooprofilattico Sperimentale della Sicilia, Via Gino Marinuzzi 3, 90129, Palermo, Italy;**  
9 **<sup>2</sup>Dipartimento di Biopatologia e Biotecnologie Mediche, sezione di biologia e genetica,**  
10 **University of Palermo, Palermo, Italy; <sup>3</sup>Department of Biomolecular Sciences, University of**  
11 **Urbino Carlo Bo, via Saffi 2, 61029 Urbino, PU, Italy.**

12

13 **Address Correspondence to: Via Gino Marinuzzi 3, 90129, Palermo, Italy**

14 **Email ardesse of all authors:**

15 **[germanocastelli@gmail.com](mailto:germanocastelli@gmail.com); [federicabruno4486@gmail.com](mailto:federicabruno4486@gmail.com); [laurasaieva@gmail.com](mailto:laurasaieva@gmail.com);**

16 **[riccardo.alessandro@unipa.it](mailto:riccardo.alessandro@unipa.it); [luca.galluzzi@uniurb.it](mailto:luca.galluzzi@uniurb.it); [aurora.diotallevi@uniurb.it](mailto:aurora.diotallevi@uniurb.it);**

17 **[fabrizio.vitale@izssicilia.it](mailto:fabrizio.vitale@izssicilia.it) (corresponding author).**

18

## 19 **Highlights**

- 20 • Exosomes are nanovesicles secreted from different cell types
- 21 • Characterization of *Leishmania infantum* exosomes are conducted in this study.
- 22 • This study demonstrates the capacity of exosomes to regulate the immune system
- 23 • *L. infantum* exosomes create an environment permissive for early infection.

24

25

26

27

## Abstract

In recent years, several studies demonstrated the role of exosomes in intercellular communications, several *Leishmania* species belonging to subgenera *Leishmania* and *Viannia* have been demonstrated to release exosomes, and their role in parasite-macrophage interactions and in leishmaniasis development has been investigated. However, the release of exosomes by *Leishmania infantum* has not been studied so far. The aim of this study was to isolate and characterize *L. infantum* exosomes, and to investigate the biological activity of these exosomes in macrophage cultures. To this end, exosomes were collected from both amastigote and promastigote *L. infantum* conditioned medium by ultracentrifugation. Exosomes were then characterized by monitoring the presence of HSP70, HSP83/90 and acetylcholinesterase activity. Moreover, nanoparticle-tracking analysis revealed that promastigote and amastigote exosomes had mean diameter of  $122 \pm 56$  nm and  $115 \pm 65$  nm, respectively. Human monocytic cell line U937-derived macrophages treated with promastigote and amastigote exosomes showed an increase in motility and an overproduction of interleukin (IL)-10 and IL-18 reduction, involved in immune response. Since *L. infantum* exosomes demonstrated the capacity to regulate the immune system, they could contribute in the disease establishment and may be considered an appropriate candidate for a vaccine therapy in prophylaxis and treatment.

**Keywords:** *Leishmania infantum*, exosomes, cytokines production

## 1 Introduction

Leishmaniasis, caused by the intracellular protozoan *Leishmania*, is a wide spread disease in tropical and subtropical areas. The parasites occur in most parts of the world and the infection is growing also in non-endemic areas. Different *Leishmania* species can cause four different clinical presentations of the disease: visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and diffuse cutaneous leishmaniasis (DCL) [1].

54 Leishmaniasis causes significant morbidity and mortality worldwide and it is an important public  
55 health problem. In the absence of effective human and canine vaccines, the only feasible way to  
56 treat and control leishmaniasis is through the use of affordable medications.

57         Recently, the exosomes secreted by the parasites have been proposed as one of the strategies  
58 used by *Leishmania* to orchestrate changes in the host environment ensuring a successful infection.  
59 Exosomes are nanovesicles secreted from different cell types, including pathogens and infected  
60 cells. In the classical pathway, exosomes are formed via the invagination of endocytic  
61 compartments generating multivesicular bodies (MVBs), and are released to the extracellular space  
62 after fusion of the MVBs with the plasma membrane [2, 3]. Despite the abundant knowledge  
63 obtained through studies using exosomes purified *in vitro* or from various biological fluids [4]  
64 observation of their formation and release *in vivo* remains a major challenge. As a consequence of  
65 their origin, exosomes contain endosome-associated proteins and proteins involved in the MVB  
66 biogenesis, such as Rab GTPases, and PDCD6IP (ALIX) or Tsg101, respectively [5]. In addition,  
67 many groups of proteins are consistently present in exosomes: heat shock proteins (HSP60, HSP70  
68 and HSP90), tetraspanins (CD81, CD63 and CD37), annexins (I, II, V and VI), cytoskeletal proteins  
69 (actin and tubulin), metabolic enzymes, proteins involved in translation (Elongation Factors 1 and  
70 2) and signaling proteins [6, 7, 8, 9, 10, 11]. Importantly, also mRNAs and microRNAs (miRNA)  
71 are present in exosomes, and are transferred to target cells [12, 13].

72         Exosomes from *Leishmania mexicana*, *L. donovani*, *L. major* and *L. braziliensis* have been  
73 shown to play a crucial role in host-pathogen interactions and were able to induce modifications in  
74 non-infected neighboring cells or act as antigen presenters for the immune system [14]. In fact,  
75 experiments performed with mice and macrophages have shown that these exosomes possess  
76 immunomodulatory and signaling-inducing activities, corroborating the presence of parasite  
77 virulence factors in their content such as the surface metalloprotease GP63 [15, 16, 17, 18].

78         Thus, it is postulated that these vesicles contribute to the multitude of factors determining the  
79 form and severity of the leishmaniasis, a spectrum of diseases that ranges from self-healing

80 cutaneous to fatal visceral forms and represents a major public health problem worldwide. The aim  
81 of this study was to isolate, characterize *L. infantum* exosomes and to investigate the biological  
82 activity of these exosomes in macrophage cultures.

83

## 84 **2 Materials and Methods**

### 85 **2.1 Parasite cultures**

86 *Leishmania infantum* promastigotes (MHON/TN/80/IPT1, MON1) taken by stock archive of  
87 the OIE Reference Laboratory National Reference Center for Leishmaniasis (C.Re.Na.L.) located in  
88 Palermo (Italy) and cultured at 25°C and pH 7.18 in RPMI-PY medium, which consisted of RPMI  
89 1640 (Sigma R0883) supplemented with equal volume of Pepton-yeast medium [19], 10%  
90 decomplexed and ultracentrifuged fetal bovine serum (FBS), 1% glutamine, 250 µg/mL  
91 gentamicin and 500 µg/mL of 5-fluorocytosine [20]. Temperature, differentiation time, and  
92 acidification of the medium were used as variables for preconditioning of the promastigote cultures.  
93 The influence of temperature was evaluated by incubating the promastigotes from 25°C at 37°C.  
94 The conditioning time for the promastigotes varied from 24 h to 72 h and the pH was acidified with  
95 1 N HCl to 5.4 to obtained amastigote parasites.

96

### 97 **2.2 Exosomes isolation**

98 Exosomes were isolated as described by Theyry et al., (2009) [9] with modifications. To collect  
99 exosomes, after 24 h, promastigotes and amastigotes forms ( $\sim 10.0 \times 10^6$  cells/mL) were removed  
100 from RPMI-PY culture media supplemented with 10% FBS by differential centrifugation. Briefly,  
101 culture medium was centrifuged subsequently for 5 min at  $300 \times g$ , 15 min at  $3,000 \times g$ , 30 min at  
102  $10,000 \times g$  and ultracentrifuged 90 min at  $100,000 \times g$  in a Type 70 Ti, fixed angle rotor. Pelleted  
103 exosomes were washed and then resuspended in PBS. To further verify the identity of vesicles as  
104 exosomes, we isolated exosomes on a 30% sucrose/D2O cushions as described by Lamparski and

105 colleagues [21]. Vesicles contained in the cushion were recovered, washed several times,  
106 ultracentrifuged for 90 min in PBS and collected for use. Exosome total protein content was  
107 determined with the Bradford assay.

### 108 **2.3 Exosomes characterization**

109 Five  $\mu\text{g}$  of total promastigotes and amastigotes forms or exosome lysates were loaded on 8 %  
110 SDS-PAGE gels for western immunoblotting. After separation, the proteins were transferred to a  
111 Nitrocellulose membrane. The nitrocellulose membrane was then blocked with 5 % milk in 1 $\times$   
112 Tris-buffered saline with 0.05 % Tween 20 (TBST) for 1 h at room temperature. Antibodies  
113 against *Leishmania* HSP70 and HSP83/90 (kindly provided by Prof. Requena, Universidad  
114 Autonoma de Madrid) were then added and incubated at 4 °C overnight. The membrane was  
115 washed in TBST and incubated with Anti-rabbit IgG, HRP-linked secondary antibody for 1 h at  
116 room temperature. An enhanced chemiluminescence (ECL) system (ThermoFisher) was used to  
117 detect the blots. The size distribution and quantification of exosome preparations were analyzed  
118 by measuring the rate of Brownian motion with a NanoSight LM10 system (NanoSight,  
119 Malverne, United Kingdom) equipped with fast video capture and particle-tracking software.  
120 Purified exosomes from amastigotes and promastigotes were diluted in 500  $\mu\text{l}$  of 1 $\times$  PBS, 5 mM  
121 EDTA and injected into a NanoSight sample cubicle. The mean  $\pm$  SD size distribution of  
122 exosomes was determined. The activity of acetylcholinesterase, an exosome marker protein, was  
123 determined as described by Savina et al. Briefly, a total of 10  $\mu\text{g}$  exosomes in 100  $\mu\text{l}$  of PBS and  
124 10  $\mu\text{g}$  total cell lysate were resuspended in a solution of 1.25 mM acetylthiocoline and 0.1 mM  
125 5,5'-dithiobis (2-nitrobenzoic acid) in a final volume of 1 mL. The incubation was carried out in  
126 cuvettes at 37 °C, and the change in absorbance at 412 nm was detected at different time points  
127 (from 0 to 90 min).

### 128 **2.4 Motility assays**

129 Migration assays were performed in transwell chemotaxis chambers with 8  $\mu\text{m}$  pore filters  
130 (NeuroProbe, Cabin John, MD, USA) [22]. Specifically, U937 cells and U937 cells differentiated  
131 into macrophages ( $0.5 \times 10^6$  cells/ well) were resuspended in 500  $\mu\text{l}$  of RPMI 1% FBS and exposed,  
132 as chemoattractant, to amastigote and promastigote exosomes (10  $\mu\text{g}/\text{mL}$ ) for 6 h at 37  $^\circ\text{C}$ . After  
133 this time, filters were removed, fixed in methanol and stained with Diff-Quick (Medion Diagnostics  
134 GmbH, Dudingen, Switzerland). Each test group was tested in three independent experiments; the  
135 number of migrating cells in five high-power fields per well were counted at 400 $\times$  magnification.

### 136 **2.5 Evaluation of cytokines production**

137 To evaluate the main cytokines production in cultures of macrophages infected with  
138 *Leishmania infantum* treated with *L. infantum* exosomes, the infection protocol described by  
139 Sharma et al. (2011) [23] was used, with some modifications. U937 monocytic cells ( $1 \times 10^5$   
140 cells/mL) in the logarithmic phase of growth were plated onto chamber Lab Tek culture slides in  
141 2.5 mL of RPMI 1640, 10% FBS, 1% glutamine medium containing 25 ng/mL of phorbol 12-  
142 myristate 13-acetate (PMA-Sigma) for 18 h to induce differentiation [24]. After incubation, the  
143 medium was removed by washing twice with RPMI-1640 medium. Non adherent cells were  
144 removed, and the macrophages were further incubated overnight in RPMI 1640 medium  
145 supplemented with 10% FBS. Then, adherent macrophages were infected with *L. infantum*  
146 promastigotes at a parasite/macrophage ratio of 5:1 for 24 h at 37  $^\circ\text{C}$  in 5%  $\text{CO}_2$ . After 24 h free  
147 promastigotes were removed by three extensive washing with RPMI-1640 medium, and infected  
148 macrophages were either incubated 24 h in media alone (infection control) or in media containing  
149 10  $\mu\text{g}/\text{mL}$  amastigote and promastigote exosomes. The production and release of macrophage  
150 cytokines (IL-10, IL-12, IFN- $\gamma$ , IL-18, IL-1 $\beta$ , IL-1 $\alpha$ , IL-4, TNF- $\alpha$ ) with and without exosomes  
151 treatment was investigated by using Human ELISA Kits for cell culture supernatants (Sigma)  
152 following the manufacturer's protocol. The samples were read using a microplate reader Spectrostar  
153 Nano (BMG Lab Tech) 450 nm immediately.

154

## 155 **2.6 Evaluation of cytokines expression**

156 Genes expression of IL-4, IL-10, IL-1 $\alpha$ , IL1- $\beta$ , IL-12, IL-18, IFN- $\gamma$  and TNF- $\alpha$ , were  
157 quantified with real-time PCR and  $\beta$ -actin was used as reference gene. After 24 h treatment with 10  
158  $\mu$ g/mL of amastigote and promastigote exosomes, total RNA was isolated from U937 cells and  
159 U937 cells differentiated, using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and reverse-  
160 transcribed by the iScript<sup>TM</sup> cDNA Synthesis Kit (Bio-Rad, Hercules, California, CA).  
161 Quantitative real-time PCR was performed using the SoFast<sup>TM</sup> EvaGreen<sup>®</sup> Supermix (Bio-Rad,  
162 Hercules, California, CA) in the StepOnePlus<sup>TM</sup> Real-Time PCR System (ABI Applied  
163 Biosystems, Foster City, CA). According to Stordeur et al. (2002), Giulietti et al. (2001) and  
164 Ramakrishna et al. (2017) [25, 26, 27] primers and taqman Probes were used to test samples in  
165 triplicate and the gene expression was calculated using the  $2^{-\Delta\Delta C_t}$  relative quantification method  
166 (Table 1). Results were expressed as fold-increase with respect to control and plotted as mean  $\pm$  SD  
167 of three independent experiments.

168

## 169 **2.6 Statistical analysis**

170 All exosomal treatment assays were performed by two observers in three replicates samples  
171 and repeated with three new batches of parasites. The mean and standard error of at least three  
172 experiments were determined. The differences between the mean values obtained for experimental  
173 groups were evaluated by the Student's t test. P-values of 0.05 or less were considered significant.  
174 Data were plotted with Microsoft Excel (Microsoft).

175

## 176 **3 Results**

177

### 178 **3.1 Characterization of *Leishmania infantum* exosomes**

179 Microvesicles from promastigotes and amastigotes form of *L. infantum* cells were purified on  
180 a 30% sucrose/D2O cushion. They were characterized by analysis of particle size, distribution,  
181 concentration, and presence of well-established exosomal protein markers. NanoSight nanoparticle  
182 tracking analysis revealed a mean particle diameter of  $122 \pm 56$  nm with a mode of 94 nm for  
183 amastigotes and a mean particle diameter of  $115 \pm 65$  nm with a mode of 76 nm for promastigotes  
184 vesicles. The presence of exosomal markers HSP70, HSP83/90 was also revealed by Western blot  
185 analyses (Fig. 1).

186 Acetylcholinesterase activity, a characteristic enzyme localized in exosomes, was found  
187 associated with the exosome fraction while negligible amounts were found in cells (Fig. 2). All  
188 these data demonstrated that *L. infantum* released exosomes.

### 189 ***3.2 Leishmania exosomes promote migration of U937 cells and macrophages derived from U937***

190 Leishmania parasites are obligate intracellular pathogens that survive and replicate into host  
191 macrophages. After the initial infection, both neutrophils and macrophages migrate to the site of  
192 infection. During the infection, the migration of macrophages play an important role in spreading  
193 the disease due to the capacity of these cells to reach several sites, such as skin, mucous membranes  
194 or internal organs. In order to understand if exosomes may have a role in promoting motility of  
195 these cells, we performed a transwell motility assay. The addition of 10  $\mu\text{g}/\text{mL}$  of promastigote and  
196 amastigote exosomes to the bottom wells caused a significant increase in the motility of U937 and  
197 U937 cells differentiated into macrophages, in particular with amastigote exosomes, compared to  
198 control (medium without exosomes) (Fig. 3). This data demonstrate that the chemotactic effects of  
199 exosomes on U937 and U937 cells differentiated into macrophages can facilitate the progression of  
200 infection.

201

### 202 ***3.3 Leishmania exosomes modulate production of cytokines***



203 The ability of exosomes to modulate the production of cytokines involved in the immune  
204 control of leishmaniasis was investigated in U937 cell line as follow: U937 monocytes and U937  
205 differentiated into macrophages, were incubated with 10 µg/mL exosomes for 24 h. Supernatants  
206 were collected and cytokines assayed by ELISA. Both EXOa and EXOp exosomes induced in  
207 monocytes significant increases in the production of IL-10 (3,6 pg/mL and 3,7 pg/mL respectively,  
208 fig. 4A). Another cytokine varied in culture medium was IL-18, in fact both EXOa and EXOp  
209 induced in monocytes significant reduction in the IL-18 production (CTL= 155,9 pg/mL,  
210 EXOa=40,7 pg/mL, EXOp=15,7 pg/mL, fig 4 C). In macrophage cells, a basal production of IL-10  
211 already occurred (CTRL=164,7 pg/mL), while the treatment with the exosomes determined an  
212 increase in the production of IL-10 both for EXOp and in a more marked way for EXOa  
213 (EXOa=338,4 pg/mL, EXOp=216,5 pg/mL, fig 4 B). There was no marked difference in IL-18  
214 production in macrophages treated with exosomes compared to CTRL (fig 4 D). Finally, EXOa and  
215 EXOp did not cause any modification in IL-12, IFN-γ, IL-4, TNF-α, IL-1 α and IL-1 β production in  
216 the cell line used. In contrast, treatment with 10 µg/mL of amastigote and promastigote exosomes  
217 for 24 h did not result in significant changes in the mRNA expression of the cytokines discussed in  
218 materials and methods (data no showed).

#### 219 **4 Discussion**

220 Leishmaniasis is a zoonotic vector-borne spectrum of diseases that can manifest from self-  
221 healing ulcers to deadly hepatosplenomegalia. The manifestation of the disease is mostly dependent  
222 on the infecting parasite species but also on the host immune system and environmental factors.  
223 Successful parasitism of the host requires effective modulation of its signaling and functions.  
224 *Leishmania* lives inside the macrophage, the professional microbe killer of the immune system,  
225 operating a complex immunomodulation and immunosubversion for successful parasitization.  
226 Alteration of macrophage signaling and function occurs at various levels, from blocking signaling  
227 pathways by activating inhibitory PTPs, to degradation of key signaling molecules such as kinases,

228 transcription factors, translation regulators and to release different forms of membrane vesicles.  
229 These signaling modulations allow for inhibition or interference with many key macrophage  
230 functions such as production of nitric oxide (NO), reactive oxygen species (ROS), cytokines and  
231 antigen presentation, resulting in perseverance of *Leishmania* in the macrophage phagolysosome.

232 Pro- and anti-inflammatory cytokines play different roles in the immunopathogenesis of  
233 *Leishmania* infection. The cytokines production, such as IL-12, IL-1, IFN- $\gamma$ , TNF- $\alpha$ , and/or IL-2,  
234 belonging to a subset of T helper 1 cytokine response, allow a eradication and a resistance to  
235 Leishmaniasis [28].

236 Recently, exosome release was investigated in different *Leishmania* species (i.e. *L. mexicana*,  
237 *L. donovani*, *L. major* and *L. braziliensis*). These exosomes were found to affect macrophage cell  
238 functions and were shown to be pro-inflammatory, showing the capacity to recruit neutrophils at  
239 their inoculation site [29]. However, to the best of our knowledge, exosomes released by *L.*  
240 *infantum* have not been studied yet. The findings reported in this study indicate that *L. infantum*  
241 release microvesicles possessing the known biochemical and morphological characteristics of  
242 mammalian exosomes. These *Leishmania* organelles contain exosomal markers (HSP 70, HSP  
243 89/90), display exosome morphology (a mean particle diameter of  $122 \pm 56$  nm with a mode of 94  
244 nm for amastigotes and a mean particle diameter of  $115 \pm 65$  nm with a mode of 76 nm for  
245 promastigotes vesicles) and migrate through a linear sucrose gradient in exactly the same manner as  
246 classical exosomes. Furthermore, with transwell-motility assay, we have shown the significant  
247 ability to increase the motility of U937 and U937 cells differentiated into macrophages. These data  
248 demonstrate the chemotactic effects of exosomes on U937 and U937 cells differentiated into  
249 macrophages, suggesting a role of exosomes in facilitating the progression of infection. Moreover,  
250 *L. infantum* exosomes (from both amastigotes and promastigotes) lead to a significant increase of  
251 IL-10 production in the U937 cell line (both monocytic and macrophage). There was also a  
252 significant reduction in IL-18 production in monocyte cells.

253 IL-10 is a cytokine produced by numerous cells of the immune system (e.g. Th1, Th2, CD8+  
254 T, B cells, Th17 and Treg cells). The association between IL-10 and Leishmaniasis susceptibility  
255 has been confirmed in several studies. Patients with visceral Leishmaniasis (VL), showed higher  
256 IL10 serological levels as well as increases in mRNA in the target organs (e.g. spleen and liver)  
257 [30].

258 Belkaid et al. (2001) showed that treatment of *L. major*-infected mice with anti-IL-10 receptor  
259 antibodies led to sterile cure and parasite clearance [31]. During VL, IL-10 could cause disease  
260 promotion mainly by conditioning the host macrophages, increasing the parasite's growth and  
261 survival. In fact, the macrophage is "silenced" by the action of the cytokine, inhibiting the  
262 amastigote killing and the down regulation the production of TNF- $\alpha$  and NO [32, 33]. IL-18 is a  
263 pleiotropic cytokine secreted by activated macrophages, DCs and Kupffer cells whose role is not  
264 well known. IL-18 acts with IL-12 to induce the development of Th1 cells. On the other hand, IL-18  
265 is also able to induce Th2 responses: Monforte et al. (2000) observed that in C57BL/6 mice IL-18  
266 gene deficient (IL-18<sup>-/-</sup>) produced strong Th1 responses and therefore a high resistance to infection  
267 from *L. major* [34]. Also in other studies, the treatment of *L. major*-infected BALB/c mice with  
268 recombinant IL-18 promotes Th2 responses in the absence of IL-4 and leads to exacerbated disease  
269 in comparison with untreated animals [35]. Moreover, during *L. major* infection in BALB/c mice,  
270 which produce a Th2 response probably due to the lack of persistent IL-12 stimulation, IL-18  
271 contributes to an increase in Th2 responses [36]. Indeed, during infection IL18 seems to carry out a  
272 Th1 or Th2 responses action based on the cytokine environment generated and host genetic  
273 background.

274 In conclusion, we showed that exosomes could regulate the immune system, adding to the  
275 repertoire of virulence factors involved in vector-transmitted infection. In particular at first by  
276 promoting the recruitment of the monocyte-macrophage line, and simultaneously performing a  
277 suppressive action against the immune system, inducing a IL-10 production and IL-18 suppression,

278 triggering a Th2 environment that allowed phagocytosis and the permanence of Leishmania parasite  
279 in the host. Since exosomes are able to contribute in the disease establishment, further studies are  
280 necessary for understanding the mechanism of infection, as they could represent a fundamental  
281 stage in preventing leishmaniasis or they could be considered an appropriate candidate for a vaccine  
282 therapy in prophylaxis and treatment.

### 283 [Abbreviations]

284 **VL**, visceral leishmaniasis; **CL**, cutaneous leishmaniasis; **MCL**, mucocutaneous  
285 leishmaniasis, **DCL**, diffuse cutaneous leishmaniasis; **MVB**, generating multivesicular bodie; **HSP**,  
286 heat shock proteins; **L.**, Leishmania; **C.Re.Na.L.**, National Reference Center for Leishmaniasis;  
287 **FBS**, fetal bovine serum; **min**, minutes; **g**, g-force; **PBS**, phosphate buffered saline; **SDS-PAGE**,  
288 sodium dodecyl sulfate polyacrylamide gel electrophoresis; **°C**, Celsius; **h**, hour; **µl**, microliter;  
289 **min**, minute, **µg**, microgramme; **ml**, milliliter; **mM**, millimolar; **µm**, micrometer; **PMA**, phorbol  
290 12- myristate 13-acetate; **IL**, interleukin; **IFN**, Interferon; **TNF**, Tumor necrosis factor; **nm**,  
291 nanometer; **EXOa**, amastigote exosomes; **EXOp**, promastigote exosomes; **pg**, picogramme;  
292 **CTRL**, control; **PTP**, Protein-tyrosine Phosphatase; **SD**, standard deviation; **NO**, nitric oxide;  
293 **ROS**, Reactive oxygen species; **Th**, Type T helper cell, **Treg**, regulatory T cells.

294

### 295 Acknowledgments

296 This research was granted by Ministry of Health “IZS SI 10/2013 RC”. The authors would  
297 like to acknowledge Prof. Requena, Universidad Autonoma de Madrid for his contributions to  
298 studies cited in this review, and Dr. Luca Macaluso for graphical support.

299

### 300 References

- 301 [1] World Health Organization. Basic Laboratory Methods in Medical Parasitology. Geneva:  
302 WHO; 1991.
- 303 [2] Bobrie, A., Colombo, M., Raposo, G., Théry, C. Exosome secretion: molecular mechanisms  
304 and roles in immune responses. *Traffic*. 2001; **12**:1659-1668.
- 305 [3] Bobrie, A., & Théry, C. Unraveling the physiological functions of exosome secretion by  
306 tumors. *Oncoimmunology*. 2013; **2**(1): e22565.
- 307 [4] Taylor, D. D., & Gercel-Taylor C. The origin, function, and diagnostic potential of RNA  
308 within extracellular vesicles present in human biological fluids. *Frontiers in*  
309 *Genetics*. 2013; **4**: 142.
- 310 [5] Saleem, S.N., Abdel-Mageed, A.B. Tumor-derived exosomes in oncogenic reprogramming  
311 and cancer progression. *Cell Mol Life Sci*. 2015; **72**(1): 1-10.
- 312 [6] Frydrychowicz, M., Kolecka-Bednarczyk, A., Madejczyk, M., Yasar, S., Dworacki, G.  
313 Exosomes – Structure, Biogenesis and Biological Role in Non-Small-Cell Lung Cancer.  
314 *Scand J Immunol*. 2015; **81**(1): 2-10.
- 315 [7] Schorey, J.S., Bhatnagar, S. Exosome function: from tumor immunology to pathogen  
316 biology. *Traffic*. 2008; **9**: 871-881.
- 317 [8] Simpson, R.J., Jensen, S.S., Lim, J.W. Proteomic profiling of exosomes: current perspectives.  
318 *Proteomics*. 2008; **8**(19): 4083-4099.
- 319 [9] They, C., Ostrowski, M., Segura, E. Membrane vesicles as conveyors of immune responses.  
320 *Nat Rev Immunol*. 2009; **9**(8): 581-593.
- 321 [10] Taylor, D.D., Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated  
322 immunosuppressive microenvironments. *Seminars in immunopathology*. 2011; **33**(5): 441-  
323 454.
- 324 [11] Yang, C., Robbins, P.D. The roles of tumor-derived exosomes in cancer pathogenesis.  
325 *Clinical & developmental immunology*. 2011; 842849.
- 326 [12] Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J.J. Exosome mediated transfer of  
327 mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nature*  
328 *cell biology*. 2007; **9**(6): 654-659.

- 329 [13] Zomer, A., Vendrig, T., Hopmans, E.S., van Eijndhoven, M., Middeldorp, J.M. Exosomes:  
330 Fit to deliver small RNA. *Communicative & integrative biology*. 2010; **3**(5): 447-450.
- 331 [14] Schorey, J.S., Cheng, Y., Singh, P.P., Smith, V.L. Exosomes and other extracellular vesicles  
332 in host-pathogen interactions. *EMBO Rep*. 2015; **16**(1): 24-43.
- 333 [15] Hassani, K., Antoniak, E., Jardim, A., Olivier, M. Temperature-induced protein secretion  
334 by *Leishmania mexicana* modulates macrophage signalling and function. *PLoS*  
335 *ONE*. 2011; **6**:18724.
- 336 [16] Hassani, K., Shio, M.T., Martel, C., Faubert, D., Olivier, M. Absence of metalloprotease  
337 GP63 alters the protein content of *Leishmania* exosomes. *PLoS ONE*, 2014; **9**:e95007.
- 338 [17] Silverman, J.M., Clos J., Horakova, E., Wang, A.Y., Wiesgigl, M., Kelly, I., Lynn M.A.,  
339 McMaster, W.R., Foster, L.J., Levings, M.K., Reiner, N.E. *Leishmania* exosomes  
340 modulate innate and adaptive immune responses through effects on monocytes and  
341 dendritic cells. *J. Immunol.*, 2010; **185**: 5011-5022.
- 342 [18] Silverman, J.M. , Reiner, N.E. Exosomes and other microvesicles in infection biology:  
343 organelles with unanticipated phenotypes. *Cell. Microbiol*. 2011; **13**: 1-9.
- 344 [19] Limoncu, M. E., Balcioglu, I. C., Yerehi, K., Ozbilgin, Y. A new experimental *in vitro*  
345 culture medium for cultivation of *Leishmania* species. *Journal of Clinical Microbiology*.  
346 1997; **35**: 2430-2431.
- 347 [20] Castelli, G., Galante, A., Lo Verde, V., Migliazzo, A., Reale, S., Lupo, T., Piazza, M.,  
348 Vitale, F., Bruno, F. Evaluation of two modified culture media for *Leishmania infantum*  
349 cultivation versus different culture media. *J. Parasitol*. 2014; **100**: 228-230.
- 350 [21] Lamparski H.G., Metha-Damani A., Yao J.Y., Patel S., Hsu D.H., Ruegg C., Le Pecq J.B.  
351 Production and characterization of clinical grade exosomes derived from dendritic cells. *J*  
352 *Immunol Methods*. 2002;270:211–226.
- 353 [22] Calvin, R. J., Nancy, L., Maria, R. E., Li, V. Y. *In vitro* Cell Migration and Invasion  
354 Assays. *J Vis Exp*. 2014; **88**: 51046.
- 355 [23] Sharma, U., Singh, D., Kumar, P., Dobhal, M. P., and Singh, S. Antiparasitic activity of  
356 plumericin & isoplumericin isolated from *Plumeria bicolor* against *Leishmania donovani*.  
357 *Indian J. Med. Res*. 2011; **134**: 709-716.

- 358 [24] Maia, C., Rolão, N., Nunes, M., Gonçalves, L., Campino, L. Infectivity of five different  
359 types of macrophages by *Leishmania infantum*. Acta Trop. 2007; **103**:150-155.
- 360 [25] Stordeur, P., Poulin, L.F., Craciun, L., Zhou, L., Schandené, L., de Lavareille, A., Goriely,  
361 S., Goldman, M. Cytokine mRNA quantification by real-time PCR. J Immunol Methods.  
362 2002; **259** (1-2): 55-64. Erratum in: J Immunol Methods. 2002; **262**(1-2): 229.
- 363 [26] Giulietti, A., Overbergh, L., Valckx, D., Decallonne, B., Bouillon, R., Mathieu, C. An  
364 overview of real-time quantitative PCR: applications to quantify cytokine gene expression.  
365 Methods. 2001; **25**(4): 386-401.
- 366 [27] Ramakrishna, V., Benjamin, W., David, L.L., Yueru, Z., Keith, A. C., David, E. G., Peter,  
367 F. B. T Cells Enhance Production of IL-18 by Monocytes in Response to an Intracellular  
368 Pathogen. J Immunol 2001; **166**:6749-6753.
- 369 [28] Maspi, N., Abdoli, A., Ghaffarifar, F. Pro- and anti-inflammatory cytokines in cutaneous  
370 leishmaniasis: a review. Pathogens and Global Health. 2016; **110**(6):247-260.
- 371 [29] Atayde, V. D., Hassani, K., da Silva Lira Filho, A., Borges, A. R., Adhikari, A., Martel, C.  
372 *Leishmania* exosomes and other virulence factors: Impact on innate immune response and  
373 macrophage functions. Cell. Immunol. 2016; **309**: 7–18.
- 374 [30] Nylén, S., Maurya, R., Eidsmo, L., Manandhar, K.D., Sundar, S., Sacks, D. Splenic  
375 accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T  
376 cells in human visceral leishmaniasis. J Exp Med. 2007; **204**(4): 805-817.
- 377 [31] Belkaid, Y., Hoffmann, K.F., Mendez, S., Kamhawi, S., Udey M.C., Wynn, T.A. The role  
378 of interleukin (IL)-10 in the persistence of *Leishmania major* in the skin after healing and  
379 the therapeutic potential of Anti-IL-10 receptor antibody for sterile cure. J Exp Med. 2001;  
380 **194**(10): 1497-1506.
- 381 [32] Vouldoukis, I., Bécherel, P.A., Riveros-Moreno, V., Arock, M., da Silva, O., Debré, P.,  
382 Mazier, D., Mossalayi, M.D. Interleukin-10 and interleukin-4 inhibit intracellular killing of  
383 *Leishmania infantum* and *Leishmania major* by human macrophages by decreasing nitric  
384 oxide generation. Eur J Immunol. 1997; **27**(4): 860-865.
- 385 [33] Wu, J., Cunha, F.Q., Liew, F.Y., Weiser, W.Y. IL-10 inhibits the synthesis of migration  
386 inhibitory factor and migration inhibitory factor-mediated macrophage activation. J  
387 Immunol. 1993; **151**(8): 4325-4332.

- 388 [34] Monteforte, G.M., Takeda, K., Rodriguez-Sosa, M., Akira, S., David, J.R., Satoskar, A.R.  
389 Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous  
390 *Leishmania major* infection. J Immunol. 2000; **164**(11):5890–5893.
- 391 [35] Xu, D., Trajkovic, V., Hunter, D., Leung, B.P., Schulz, K., Gracie, J.A. IL-18 induces the  
392 differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic  
393 background. Eur J Immunol. 2000; **30**(11): 3147-3156.
- 394 [36] Wei, X.-Q., Niedbala, W., Xu, D., Luo, Z.-X., Pollock, K.G.J., Brewer, J.M. Host genetic  
395 background determines whether IL-18 deficiency results in increased susceptibility or  
396 resistance to murine *Leishmania major* infection. Immunol. Lett. 2004; **94**: 35-37.